Energenesis Biomedical Co., Ltd. (6657) Stock Price & Analysis
6657 Stock Chart & Stats
- Day’s Range
- TWD 27.00 - TWD 29.90
- 52-Week Range
- TWD 27.00 - TWD 59.70
- Previous Close
- TWD 29.95
- Volume
- N/A
- Average Volume (3M)
- 117.66K
- Market Cap
- TWD 2.66B
- Enterprise Value
- TWD 2.53B
- Total Cash (Recent Filing)
- TWD 677.38M
- Total Debt (Recent Filing)
- TWD 11.74M
- Price to Earnings (P/E)
- ―
- Beta
- 0.55
- Next Earnings
- Nov 17, 2026 (Est.)
- EPS Estimate
- -0.54
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6657 FAQ
What was Energenesis Biomedical Co., Ltd.’s price range in the past 12 months?
What is Energenesis Biomedical Co., Ltd.’s market cap?
When is Energenesis Biomedical Co., Ltd.’s upcoming earnings report date?
How were Energenesis Biomedical Co., Ltd.’s earnings last quarter?
Is Energenesis Biomedical Co., Ltd. overvalued?
Does Energenesis Biomedical Co., Ltd. pay dividends?
What is Energenesis Biomedical Co., Ltd.’s EPS estimate?
How many shares outstanding does Energenesis Biomedical Co., Ltd. have?
What happened to Energenesis Biomedical Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Energenesis Biomedical Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Energenesis Biomedical Co., Ltd.
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Han-min Chen
- Employees
- 35
- Website
- www.energenesis-biomedical.com
- Address
- No.21, Ln.583, Ruiguang Road, Taipei, TP, 11492, TW
Energenesis Biomedical Co., Ltd. (6657) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |

